



Luminous Mind, Inc. Announces the Appointment of Dr. Bert Spilker as a New Board Member

Bert Spilker, Ph.D., M.D., FCP, FFPM brings to Luminous Mind his remarkable range of knowledge and 40-year experience advising FDA, NIH and multiple drug development programs world-wide.

Boston – February 27, 2024. Luminous Mind, Inc. announces the appointment of [Dr. Bert Spilker](#) to the board of directors. Founded in 2021, Luminous Mind Inc. has assembled an experienced team of drug hunters to identify new chemical treatments for [neuropsychiatric disorders of the central nervous system](#) such as anxiety, depression, chronic pain, PTSD, anorexia and schizophrenia.

Louis Herlands, Ph.D., CEO, of Luminous Mind, expressed his enthusiasm about Dr. Spilker's appointment, noting that his extensive expertise in drug development and regulatory affairs will greatly benefit Luminous Mind's strategic initiatives in neuropsychiatric disorder treatment and rare diseases. "I have known and worked with Dr. Bert Spilker for over 3 decades, and he is going to be instrumental in helping us build and advance our pipeline of impactful medicines", said Louis.



Dr. Spilker's 15 textbooks on drug development are required reading in the pharmaceutical industry. Dr. Spilker was the Senior Vice President of Scientific and Regulatory Affairs for PhRMA (Pharmaceutical Research and Manufacturers of America) based in Washington, D.C. He was President and Co-Founder of Orphan Medical, Inc., a public pharmaceutical company that brought 7 drugs for patients with uncommon diseases to market in five years.

His service on the Steering Committee for the International Conference on Harmonization received numerous honors including the FDA Commissioner's Special Citation for work in the orphan medicine area. His medical training in pharmacology and internal medicine was at Cornell Medical College, SUNY; UCSF, U. Miami Medical School (Ph.D. to M.D. Program) and Brown University Medical School.

Dr. Spilker said "I am excited to work with Dr. Herlands and the Luminous Mind team, many of whom I have known for years. The novel program of Luminous Mind has the potential to make a major contribution to medical practice through the development and marketing of significant new therapies."

About Luminous Mind Inc.

Luminous Mind Inc., with its focus on Central Nervous System (CNS) disorders, applies a rigorous therapeutic discovery and development process that includes the repurposing of existing, abandoned, and developmental compounds for new indications. Groundbreaking scientific insights in neuroscience, genetics, systems biology, and brain circuitry, together with powerful new tools drive its discovery efforts. For additional information, please visit www.LuminousMindInc.com.

Contact:

Louis Herlands, PhD
Chairman and CEO
LHerlands@LuminousMindInc.com
P: 800-816-9630 x702
Cambridge, MA